Skip to content
Education Training, Medical Health Aged Care

Tuesday 20 May: $50M donation to establish world-first Endometriosis Research Institute

UNSW Sydney < 1 mins read

On Tuesday, 20 May, UNSW Sydney will announce the Ainsworth Endometriosis Research Institute (AERI) – a world-first, multidisciplinary initiative made possible by a record-breaking $50 million philanthropic donation from the Ainsworth family.

This major partnership positions Australia as a global leader in endometriosis research and women’s health, aiming to fast-track diagnosis, improve treatments and change outcomes for the estimated 200 million people living with the disease globally.

Announcement event (media welcome – not for publication):

Date: Tuesday 20 May 2025
Location: The Lounge at UNSW (Level 11, UNSW Sydney Library Building, parking available)
Time: From 10:30am. The event starts at 11:15am, arrive by 10:45am to access broadcast equipment

Speakers include:

- Anna and Lily Ainsworth, donors and advocates

- Case studies with lived experience of endometriosis
- Professor Attila Brungs, Vice-Chancellor and President, UNSW Sydney

- Professor Jason Abbott, Clinical Academic, UNSW Women’s Health
- Professor Caroline Ford, Gynaecological Cancer Research Group Lead, UNSW Sydney
- David Gonski AC, Chancellor, UNSW Sydney

 

A media Q&A with lead researchers, UNSW representatives and an endometriosis patient will take place following the announcement

 


Key Facts:

- One in seven Australian women will be diagnosed with endometriosis by age 49
- AERI will use precision medicine and global research collaboration to drive breakthroughs
- The AERI Institute is the largest known philanthropic gift to women’s health in Australia

A press kit with B-Roll, stills and additional information about AERI is available on request  


Contact details:

Larissa Baiocchi, UNSW Head of Communications
Phone: 0452 229 349, Email: [email protected]

Please RSVP to confirm attendance 

Media

More from this category

  • Medical Health Aged Care
  • 07/12/2025
  • 01:41
Takeda Pharmaceutical Company Limited

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera

52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline NEWARK,…

  • Medical Health Aged Care
  • 06/12/2025
  • 02:11
Arthur D. Little

Arthur D. Little and Vega IT Unveil Joint Venture for Digital Innovation

NEW YORK–BUSINESS WIRE– Arthur D. Little (ADL) and Vega IT today announced the formation of Axceler8 Solutions, a 50/50 joint venture created to design,…

  • Contains:
  • Medical Health Aged Care, Women
  • 05/12/2025
  • 10:11
Breast Cancer Trials

Bec’s Christmas wish amid cancer treatment

This Christmas, Bec’s wish is for her daughters to never face a breast cancer diagnosis like she has. “The only thing tougher than telling…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.